LIU HUAQING,BLACK LAWRENCE A.,BENNANI YOUSSEF L.,COWART MARLON D.
申请号：
NZ61132307
公开号：
NZ611323A
申请日:
2007.06.22
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
Disclosed are 1-phenyl-2-aminoalkyl-cyclopropane derivatives as represented by the general formula (I), or a pharmaceutically acceptable salt, ester, or amide thereof, wherein the substituents are as defined in the specification. Representative compounds include 2-methyl-5-[4-((1S,2S)-2-{ [(2S)-2-methylpyrrolidin-1-yl]methyl} cyclopropyl)phenyl]-1,3-benzothiazole N-[4-((1S,2S)-2-{ [(2S)-2-methylpyrrolidin-1-yl]methyl} cyclopropyl)phenyl]-5-(trifluoromethyl)thieno[3,2-b]pyridine-6-carboxamide, or a salt thereof. Further disclosed is a composition comprising a compound as defined above, and a pharmaceutically acceptable carrier for the treatment of conditions such as attention-deficit hyperactivity disorder (ADHD), deficits in attention, dementia, and diseases with deficits of memory, learning, schizophrenia, cognitive deficits of schizophrenia, cognitive deficits and dysfunction in psychiatric disorders, Alzheimer&rsquos disease, mild cognitive impairment, epilepsy, seizures, allergic rhinitis, and asthma, motion sickness, dizziness, Meniere&rsquos disease, vestibular disorders, vertigo, obesity, diabetes, type II diabetes, Syndrome X, insulin resistance syndrome, metabolic syndrome, pain, including neuropathic pain, neuropathy, sleep disorders, narcolepsy, pathological sleepiness, jet lag, drug abuse, mood alteration, bipolar disorder, depression, obsessive compulsive disorder, Tourette&rsquos syndrome, Parkinson&rsquos disease, and medullary thyroid carcinoma, melanoma, and polycystic ovary syndrome.
